Nature Communications (Jan 2021)

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia

  • Hu Lei,
  • Han-Zhang Xu,
  • Hui-Zhuang Shan,
  • Meng Liu,
  • Ying Lu,
  • Zhi-Xiao Fang,
  • Jin Jin,
  • Bo Jing,
  • Xin-Hua Xiao,
  • Shen-Meng Gao,
  • Feng-Hou Gao,
  • Li Xia,
  • Li Yang,
  • Li-Gen Liu,
  • Wei-Wei Wang,
  • Chuan-Xu Liu,
  • Yin Tong,
  • Yun-Zhao Wu,
  • Jun-Ke Zheng,
  • Guo-Qiang Chen,
  • Li Zhou,
  • Ying-Li Wu

DOI
https://doi.org/10.1038/s41467-020-20259-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 16

Abstract

Read online

Resistance to tyrosine kinase inhibitors (TKI) is a limitation to their use in treating chronic myelogenous leukemia (CML). Here, the authors show that targeting the ubiquitin peptidase USP47 overcomes TKI resistance and eliminates leukaemia stem/progenitor cells in primary and xenograft CML murine models.